Relapsed/Refractory Multiple Myeloma: Optimizing Early Use of CAR T-Cell Therapy

Dr. Joshua Richter and Dr. Marco Davila discuss the rationale for incorporating CAR T-cell therapy earlier in the treatment course for relapsed/refractory multiple myeloma (RRMM). Dr. Davila explains that earlier use of cellular therapy, particularly in the second or third line of treatment, may improve outcomes by treating patients with lower disease burden, fewer cumulative toxicities, and more treatment-sensitive disease. He emphasizes that earlier intervention can simplify treatment planning and increase the likelihood of achieving durable, high-quality remissions. The discussion also addresses how patient-specific factors, including age, comorbidities, and anticipated treatment-related toxicities, may influence the selection of a particular cellular therapy product. While acknowledging that treatment decisions should remain individualized, Dr. Davila reiterates that his guiding principle is to consider cellular therapy as early as appropriate, balancing efficacy, safety, and patient characteristics to optimize long-term outcomes in RRMM.